Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan + mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07214298Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pegcetacoplan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Roswell Park Comprehensive Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07214298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214298.